Enhancing Ticagrelor Solubility Through the Solid Dispersion Method
Abstract
Abstract Views: 692
Ticagrelor (TCG) is a pharmaceutical drug used for the treatment of acute coronary syndrome, angina, and stroke. It has low solubility and less permeability and is classified as a BCS (Biopharmaceutical Classification System) Class IV drug. It has low water solubility. So, there is a need to increase the solubility of this drug. Hence, this study was aimed to augment the solubility of TCG using various approaches. Furthermore, solid dispersion of the drug and carriers was prepared and various preparations were estimated for several parameters, including phase solubility, drug release, and chemical compatibility. For this purpose, different chemicals were used including polyethylene glycol-6000 (PEG-6000), poloxamer 407 (PLX), β-cyclodextrin (β-CD), Transcutol-P (TP), Tween-80, and ethanol. Particle size reduction, complexation, change in pH, co-solvency, and solid dispersion via solvent evaporation and kneading were used to improve the solubility of TCG. According to the findings, there was no significant change in the absorbance value of the drug at different pH. The FTIR spectra did not show the emergence of new peaks indicating the drug's and carriers’ chemical compatibility. Moreover, PLX plays a major role in enhancing the solubility of TCG. Furthermore, the phase solubility of all formulations augmented with the increase of ethanol because TCG is soluble in ethanol. These outcomes imply that all these techniques may serve as effective means for enhancing TCG’s solubility.
Downloads
References
Markovic M, Zur M, Ragatsky I, Cvijić S, Dahan A. BCS class IV oral drugs and absorption windows: regional-dependent intestinal permeability of furosemide. Pharmaceutics. 2020;12(12):e1175. https://doi.org/10.3390/pharmaceutics12121175
Aziz A, Zaman M, Khan MA, et al. Preparation and evaluation of a self-emulsifying drug delivery system for improving the solubility and permeability of ticagrelor. ACS Omega. 2024;9(9):10522–10538. https://doi.org/10.1021/acsomega.3c08700
Jansook P, Ogawa N, Loftsson T. Cyclodextrins: structure, physicochemical properties and pharmaceutical applications. Int J Pharmaceutics. 2018;535(1-2):272–284. https://doi.org/10.1016/j.ijpharm.2017.11.018
Bayoumi AA. Enhancement of solubility of a poorly soluble antiplatelet aggregation drug by cogrinding technique. Asian J Pharm Clin Res. 2018;11(10):340–344.
Stella V, Borchardt R, Hageman M, Oliyai R, Maag H, Tilley J, eds. Prodrugs: Challenges and Rewards. Springer Science & Business Media; 2007.
Murtaza G. Solubility enhancement of simvastatin: a review. Acta Pol Pharm. 2012;69(4):581–590.
Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. New Eng J Med. 2019;381(21):2032–2042. https://doi.org/10.1056/NEJMoa1908419
Saokham P, Muankaew C, Jansook P, Loftsson T. Solubility of cyclodextrins and drug/cyclodextrin complexes. Molecules. 2018;23(5):e1161. https://doi.org/10.3390/molecules23051161
Yuan D, Zhang C, Tang S, et al. Fe3+-sulfite complexation enhanced persulfate Fenton-like process for antibiotic degradation based on response surface optimization. Sci Total Environ. 2020;727:e138773. https://doi.org/10.1016/j.scitotenv.2020.138773
Kim M, Sahu A, Kim GB, et al. Comparison of in vivo targeting ability between cRGD and collagen-targeting peptide conjugated nano-carriers for atherosclerosis. J Control Release. 2018;269:337–346. https://doi.org/10.1016/j.jconrel.2017.11.033
Samadi A, Hasanzadeh R, Azdast T, Abdollahi H, Zarrintaj P, Saeb MR. Piezoelectric performance of microcellular polypropylene foams fabricated using foam injection molding as a potential scaffold for bone tissue engineering. J Macromol Sci. 2020;59(6):376–389. https://doi.org/10.1080/00222348.2020.1730573
Shaikh A, Bhide P, Nachinolkar R. Solubility enhancement of celecoxib by solid dispersion technique and incorporation into topical gel. Asian J Pharm Clin Res. 2019;12:294–300.
Shi H, Xie Y, Xu J, Zhu J, Wang C, Wang H. Solubility enhancement, solvent effect and thermodynamic analysis of pazopanib in co-solvent mixtures. J Chem Thermodyn. 2021;155:e106343. https://doi.org/10.1016/j.jct.2020.106343
Rajabzadeh P, Ghanbarpour P, Rahimpour E, et al. Non-Electrostatic energies as a metric for prediction of deferasirox solubility in binary solvent mixtures: polarized continuum model tactic. J Mol Liq. 2021;339:e115791. https://doi.org/10.1016/j.molliq.2021.115791
Mukherji D, Marques CM, Kremer K. Collapse in two good solvents, swelling in two poor solvents: defying the laws of polymer solubility? J Phys Condens Matter. 2017;30(2):e024002. https://doi.org/10.1088/1361-648X/aa9c77
Wallat JD, Harrison JK, Pokorski JK. pH responsive doxorubicin delivery by fluorous polymers for cancer treatment. Mol Pharmaceutics. 2018;15(8):2954–2962. https://doi.org/10.1021/acs.molpharmaceut.7b01046
Ding L, Jiang Y, Zhang J, Klok H-A, Zhong Z. pH-sensitive coiled-coil peptide-cross-linked hyaluronic acid nanogels: synthesis and targeted intracellular protein delivery to CD44 positive cancer cells. Biomacromolecules. 2018;19(2):555–562. https://doi.org/10.1021/acs.biomac.7b01664
Rinaki E, Valsami G, Macheras P. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res. 2003;20:1917–1925. https://doi.org/10.1023/B:PHAM.0000008037.57884.11
Mircioiu C, Voicu V, Anuta V, et al. Mathematical modeling of release kinetics from supramolecular drug delivery systems. Pharmaceutics. 2019;11(3):e140. https://doi.org/10.3390/pharmaceutics11030140
Nayak AK, Panigrahi PP. Solubility enhancement of etoricoxib by cosolvency approach. ISRN Phys Chem. 2012;2012(1):e820653. https://doi.org/10.5402/2012/820653
Muller R, Bohm B, Grau J, Wise D. Nanosuspensions: a formulation approach for poorly soluble and poorly bioavailable drugs. In: Wise DL, ed. Handbook of Pharmaceutical Controlled Release Technology. CRC Press; 2000:345–357.
Wang X, Luo Z, Xiao Z. Preparation, characterization, and thermal stability of β-cyclodextrin/soybean lecithin inclusion complex. Carbohydr Polym. 2014;101:1027–1032. https://doi.org/10.1016/j.carbpol.2013.10.042
Zheng Y, Eli W, Li G. FTIR study of Tween80/1-butyl-3-methylimidazolium hexafluorophosphate/toluene microemulsions. Colloid Polym Sci. 2009;287:871–876. https://doi.org/10.1007/s00396-009-2044-x
Newa M, Bhandari KH, Li DX, et al. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. Int J Pharmaceutics. 2007;343(1-2):228–237. https://doi.org/10.1016/j.ijpharm.2007.05.031
Benyacoub A, Skender A, Boutemak K, Hadj-Ziane-Zafour A. Inclusion complexes of Melia azedarach L. seed oil/β-cyclodextrin polymer: preparation and characterization. Chem Zvesti. 2019;73:525–534. https://doi.org/10.1007/s11696-018-0600-x
Htun WW, Steinhubl SR. Ticagrelor: the first novel reversible P2Y12 inhibitor. Expert Opin Pharmacother. 2013;14(2):237–245. https://doi.org/10.1517/14656566.2013.757303
Dangas G, Baber U, Sharma S, et al. Ticagrelor with or without aspirin after complex PCI. J Am Coll Cardiol. 2020;75(19):2414–2424.
Na Y-G, Byeon J-J, Kim M-K, et al. Pharmacokinetic/pharmacodynamic modeling to predict the antiplatelet effect of the ticagrelor-loaded self-microemulsifying drug delivery system in rats. Mol Pharm. 2020;17(4):1079–1089. https://doi.org/10.1021/acs.molpharmaceut.9b00964
Liu J, Liu Q, Yang C, et al. cRGD-modified benzimidazole-based pH-responsive nanoparticles for enhanced tumor targeted doxorubicin delivery. ACS Appl Mater Interfaces. 2016;8(17):10726–10736. https://doi.org/10.1021/acsami.6b01501
Henriksson R, Björklund F, Mooe T. The introduction of ticagrelor is associated with lower rates of recurrent ischemic stroke after myocardial infarction. PLoS One. 2019;14(5):e0216404. https://doi.org/10.1371/journal.pone.0216404
Mohammed IA, Ghareeb MM. Investigation of solubility enhancement approaches of ticagrelor. Iraqi J Pharm Sci. 2018;27(1):8–19. http://dx.doi.org/10.31351/vol27iss1pp8-19
Zhou X, Xu L, Xu J, et al. Construction of a high-efficiency drug and gene co-delivery system for cancer therapy from a pH-sensitive supramolecular inclusion between oligoethylenimine-graft-β-cyclodextrin and hyperbranched polyglycerol derivative. ACS Appl Mater Interfaces. 2018;10(42):35812–35829. https://doi.org/10.1021/acsami.8b14517
Zhang X, Huang Y, Ghazwani M, et al. Tunable pH-responsive polymeric micelle for cancer treatment. ACS Macro Lett. 2015;4(6):620–623. https://doi.org/10.1021/acsmacrolett.5b00165
Hu Q-D, Tang G-P, Chu PK. Cyclodextrin-based host–guest supramolecular nanoparticles for delivery: from design to applications. Acc Chem Res. 2014;47(7):2017–2025. https://doi.org/10.1021/ar500055s
Coughlan J, Aytekin A, Ndrepepa G, et al. Ticagrelor or prasugrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention. Circ Cardiovasc Interv. 2021;14(7):e010565. https://doi.org/10.1161/CIRCINTERVENTIONS.121.010565
Copyright (c) 2024 Saba Akram, Muhammad Zaman, Mahpara Almas, Syeda Aamna Hassan, Waqar Siddique
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal
